Clinical trial NCT01498822: Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
Official title: A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Epilepsy
Keywords: Levetiracetam
Oxcarbazepine
treatment failure
partial epilepsy
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2011-12-23
Enrollment: 353
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose

Detailed description: The study duration consists of the following periods:

* Baseline period of one week: Week -1
* Titration period of two weeks: Week 0 to Week 1
* Treatment period of 48 weeks: Week 2 to Week 50

Eligibility criteria: Inclusion Criteria:

* Male or female subjects from 16 to 80 years, inclusive. Vulnerable subjects (e.g., under 20 years or subject with learning disability but judged to be capable to understand) may only be included where legally permitted and ethically accepted
* Subjects with newly or recently diagnosed epilepsy having experienced unprovoked partial seizures (IA, IB, IC with clear focal origin), that are classifiable according to the International Classification of Epileptic seizure (1981). Undiscriminated subjects between IC and IIE could be included
* Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year preceding randomization out of which at least 1 unprovoked seizure in the 6 months preceding randomization
* Subjects with documented evidence of EEG and brain MRI or CT scan in medical records which were performed within 1 year prior to Visit 1 (V1)
* Subjects have no treatment with anti-epileptic drugs in the 6 months preceding this study. The treatment for acute seizure control is acceptable with a maximum of 2 weeks duration and if the treatment was stopped at least 1 week before V1. For Phenobarbital and Phenobarbital derivatives, a minimum of 4 weeks wash-out is requested before V1

Exclusion Criteria:

* Subject has a current or previous diagnosis of pseudoseizures, conversion disorders, or other non-epileptic ictal events which could be confused with seizures
* Subject taking 1 or more of the following medications on a regular basis within 28 days prior to Visit 1: neuroleptics, monoamine oxidase (MAO) inhibitors and narcotic analgesics
* Subject taking any immunosuppressant within 28 days prior to Visit 1
* Subject has a history of suicide attempt, has received professional counseling for suicidal ideation, or is currently experiencing active suicidal ideation
* Subject has a seizure disorder characterized primarily by isolated auras (ie, simple partial seizures without observable motor signs)
* Subject suffering from seizures other than partial (IA, IB, IC, with clear focal origin) seizures
* Subject has a history of status epilepticus within last 3-month period prior to Visit 1
* Subject has seizures that are uncountable due to clustering (ie, an episode lasting less than 30 minutes in which several seizures occur with such frequency that the initiation and completion of each individual seizure cannot be distinguished) during the 12-week period prior to Visit 1 and/or during the Screening Period
* Body weight is lower than 40 kg (\< 40 kg)

Primary outcomes:
measure: Percentage of Subjects With a Treatment Failure
timeFrame: Week 0 (First Dose) to Week 50
Secondary outcomes:
measure: Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period
timeFrame: From Week 2 to Week 50 (During Treatment Period )
measure: Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time
timeFrame: From Week 2 to Week 50 (During Treatment Period )
measure: Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period
timeFrame: From Week 2 to Week 50 (During Treatment Period )
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: 05
city: Busan
country: Korea, Republic of
facility: 10
city: Busan
country: Korea, Republic of
facility: 16
city: Daejeon
country: Korea, Republic of
facility: 06
city: Daejeon
country: Korea, Republic of
facility: 18
city: Gangwon-Do
country: Korea, Republic of
facility: 23
city: Goyang-si
country: Korea, Republic of
facility: 08
city: Goyang-si
country: Korea, Republic of
facility: 09
city: Gwangju
country: Korea, Republic of
facility: 07
city: Jung-Gu
country: Korea, Republic of
facility: 22
city: Seongnam-si
country: Korea, Republic of
facility: 14
city: Seoul
country: Korea, Republic of
facility: 01
city: Seoul
country: Korea, Republic of
facility: 02
city: Seoul
country: Korea, Republic of
facility: 03
city: Seoul
country: Korea, Republic of
facility: 04
city: Seoul
country: Korea, Republic of
facility: 11
city: Seoul
country: Korea, Republic of
facility: 12
city: Seoul
country: Korea, Republic of
facility: 13
city: Seoul
country: Korea, Republic of
facility: 15
city: Seoul
country: Korea, Republic of
facility: 17
city: Seoul
country: Korea, Republic of
facility: 20
city: Seoul
country: Korea, Republic of
facility: 21
city: Ulsan
country: Korea, Republic of
facility: 19
Study officials:
affiliation: +1 877 822 9493 (UCB)
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
citation: Kim JH, Lee SK, Loesch C, Namgoong K, Lee HW, Hong SB; Korean N01367 Study Group. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial. Epilepsia. 2017 Apr;58(4):e70-e74. doi: 10.1111/epi.13707.